Figure 7. MiR-143-3p treatment inhibits inflammation and the progression of arthritis in CIA mice.
DBA/1J mice were immunized with bovine type II collagen emulsified in complete Freund adjuvant and incomplete Freund adjuvant. Mice were treated at day 28 and day 35 after the first immunization with saline (1 ml/kg) or miR-143-3p mimics negative control (2 mg/kg) or miR-143-3p mimics (2 mg/kg).
(A-C) Mean arthritis score and paw thickness in CIA mice treated with mimics control or miR-143-3p mimics. Data were expressed as the mean ± SEM (n=6). * p < 0.05, **p < 0.01, by one-way ANOVA with Dunnett’s post-hoc test.
(D) Representative histopathological characteristics in the joints of miR-143-3p-treated CIA mice.
(E-F) Histological scores and the number of TRAP-positive cells in the joints of miR-143-3p-treated CIA mice. Data were expressed as the mean ± SEM (n=6). * p < 0.05, **p < 0.01 compared with the control mimics group by Student’s t test.
(G) MiR-143-3p expression in CIA mice with miR-143-3p mimics or mimics control detected by qPCR analysis. Data were expressed as the mean ± SEM (n=6). * p < 0.05, **p < 0.01 compared with the control mimics group by Student’s t test.
(H) The plasma levels of IL-1β, IL-6, TNF-α, IL-17A in CIA mice with miR-143-3p mimics or mimics control measured by ELISA. Data were expressed as the mean ± SEM (n=6). * p < 0.05, **p < 0.01 compared with the control group by Student’s t test.